SALURAN DARURAT: +603 7620 7979 / +603 7787 2992
beacon hospital logo

Beacon Hospital Marks Major Milestone in Prostate Cancer Therapy

Home / Beacon Hospital Marks Major Milestone in Prostate Cancer Therapy
18/11/2025

Beacon Hospital has achieved a groundbreaking milestone in prostate cancer care by successfully administering the first dose of Radioligand Therapy to our first clinical trial patient. This historic moment marks a major step forward in targeted prostate cancer treatment, offering new hope for patients battling this disease.

Our commitment to innovation, precision, and patient-centered care drives every breakthrough. Radioligand Therapy represents the future of prostate cancer treatment, combining advanced technology with life-changing impact.

This milestone isn’t just about treatment—it’s about transforming lives, expanding possibilities, and pushing the boundaries of modern prostate cancer care. Together, we continue to advance medical research and bring hope and healing to every patient we serve.

Share This Article!
Latest Highlights
Latest Articles

Informasi

Jam Kunjungan:
10:00 – 22:00
Saluran Umum:
+603 7620 7979 +603 7787 2992
Saluran Janji Temu Konsultan:
+603 7118 7878 +6012 328 6913
Email:
info@beaconhospital.com.my
Pertanyaan Karir / SDM:
joinus@beaconhospital.com.my

Beacon Hospital Sdn. Bhd.

200301019556 (621976-D)
1, Jalan 215, Seksyen 51,
Off Jalan Templer,
46050 Petaling Jaya, Selangor.

Langganan Buletin Kami

Tetap terinformasi dengan tren kesehatan terbaru, saran ahli, dan acara terkini di Rumah Sakit Beacon.

Langganan Buletin Kami

Tetap terinformasi dengan tren kesehatan terbaru, saran ahli, dan acara terkini di Rumah Sakit Beacon.
© 2025 Beacon Hospital (寶康医院). SDN. BHD. 200301019556 (621976-D) | (KKLIU 3340/2025)

Subscribe for Exclusive Medical & Health Insight - Straight to Your Inbox

Stay up-to-date with the latest healthcare trends, expert advice and latest events at Beacon Hospital. Our newsletter brings you health tips and news to keep you informed and inspired - let's subscribe now!